Skip to content

The physiological role of bile acid‐mediated glucagon‐like peptide‐1 release in humans: The Cerebrotendinous Xanthomatosis Mixed Meal Test study.

The physiological role of bile acid‐mediated glucagon‐like peptide‐1 release in humans: The Cerebrotendinous Xanthomatosis Mixed Meal Test study.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON23193
Enrollment
28
Registered
2011-01-24
Start date
2011-04-01
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes, insulin resistance

Interventions

Mixed meal test: Liquid meal test (standard protocol) during which blood withdrawals are taken for 2-4 hours to measure glucose, insulin, bile acids and incretins.

Sponsors

AMC
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Inclusion criteria, CTX patients: 1. Adult age (older than 18 years of age); 2. Body mass index 19‐30 kg/m2; 3. General good health (normal liver and renal function); 4. HbA1c below 7%; 5. Ability to give informed consent. Inclusion criteria, matched controls: Matched to CTX patients on individual basis. Preferably, these controls are unaffected healthy relatives to prevent differences in environmental factors (diet, faecal microbial composition, activity). If this is not possible, healthy matched control (age, length, height, gender) will be recruited.

Exclusion criteria

Exclusion criteria: Since CTX is a rare disorder, little exclusion criteria exist. However, patients that use medication that interferes with glucose metabolism such as oral antidiabetic medication or insulin are not included.

Design outcomes

Primary

MeasureTime frame
Glucose, bile acids and incretins during meal test.

Secondary

MeasureTime frame
Energy expenditure.

Contacts

Public ContactM.R. Soeters

Academic Medical Center (AMC) Department of Endocrinology & Metabolism, F5-162 P.O. Box 22660

m.r.soeters@amc.uva.nl+31 (0)20 5669111

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)